Phase Ⅰ/Ⅱa Trial Evaluating Intravenous hUC-MSCs Injection for Safety, Tolerability and Efficacy in Patients With POI
Phase Ⅰ/Ⅱa Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of Intravenous Injection of Human Umbilical Cord Mesenchymal Stem Cells (hUC-MSCs) in Patients With Premature Ovarian Insufficiency (POI)
A Phase I/IIa clinical study evaluating the safety, tolerability and efficacy of intravenously administered human umbilical cord mesenchymal stem cell (hUC-MSCs) injection in patients with premature ovarian insufficiency (POI).
The primary objective of the Phase I dose-escalation stage is to assess the safety and tolerability of intravenous infusion of hUC-MSCs injection for the treatment of POI, and to determine the recommended phase II dose (RP2D) for the Phase IIa clinical trial.
The primary objective of the Phase IIa dose-expansion stage is to evaluate the efficacy of intravenous infusion of hUC-MSCs injection in POI treatment, and to generate data to support pivotal/confirmatory clinical trials.
研究概览
详细说明
Premature ovarian insufficiency (POI) is defined as ovarian dysfunction occurring in women before the age of 40, which is mainly characterized by menstrual abnormalities (amenorrhea, oligomenorrhea or polymenorrhea), elevated gonadotropin levels (FSH > 25 U/L), and fluctuating decline in estrogen levels. The incidence of POI is age-specific: 1 in 250 women develops POI before 35 years of age, and 1 in 100 women develops POI before 40 years of age. The incidence rate of POI in China is 2.8%, showing an upward trend year by year with a younger onset age.
hormone replacement therapy (HRT) relieves symptoms caused by low estrogen through estrogen supplementation. Sequential estrogen-progestogen therapy is recommended for POI patients with an intact uterus. Since patients with POI require long-term HRT, natural or nearly natural estrogens and progestogens can be selected to minimize adverse effects on the mammary gland, metabolism, cardiovascular system and other systems. Nevertheless, HRT still increases the risks of breast cancer, heart disease and stroke.
Studies have demonstrated that mesenchymal stem cells can home to ovarian stroma, regulate the balance of Th1/Th2 cytokines and the expression of endometrial natural killer cells, alleviate inflammatory responses, inhibit apoptosis of ovarian granulosa cells and reduce ovarian interstitial fibrosis, thereby improving the ovarian microenvironment. Meanwhile, these cells can secrete growth factors including VEGF, IGF-1 and HGF, promote proliferation of various ovarian cells and angiogenesis, repair ovarian structure and restore ovarian ovarian function. This study aims to evaluate the safety, tolerability and efficacy of intravenously administered hUC-MSCs in the treatment of patients with POI.
研究类型
注册 (估计的)
阶段
- 阶段2
- 阶段1
联系人和位置
学习联系方式
- 姓名:Xiaohong Wang,MD
- 电话号码:+86 755 6683 5786
- 邮箱:xiaohong@wingor.net
学习地点
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国、100730
- 招聘中
- Peking Union Medical College Hospital
-
接触:
- Qi Yu, Prof.
- 电话号码:+86 10 6915 8621
- 邮箱:yuqimd@163.com
-
-
参与标准
资格标准
适合学习的年龄
- 成人
接受健康志愿者
描述
Inclusion Criteria:
- Aged 18 to 40 years at the time of signing the informed consent form (exclusive of the boundary values);
- Meet the diagnostic criteria specified in the Expert Consensus on Clinical Diagnosis and Treatment of Premature Ovarian Insufficiency (2023 Edition): oligomenorrhea (menstrual cycle longer than 35 days) or amenorrhea for more than 4 months, with basal serum follicle-stimulating hormone (FSH) > 25 U/L (tested on Days 2-4 of the menstrual cycle or during amenorrhea, at least twice with an interval of ≥4 weeks);
Satisfy one of the following two criteria:
- Total number of antral follicles (AFC) with a diameter of 2-10 mm in bilateral ovaries < 5;
- Serum anti-Müllerian hormone (AMH) ≤ 7.85 pmol/L (equivalent to 1.1 ng/mL);
- Have received standardized hormone replacement therapy (HRT) at a stable dose for ≥3 months prior to drug administration with stable hormone levels, and maintain stable HRT per medical advice throughout the trial (within 24 weeks after enrollment);
- Have no fertility requirements;
- Agree to use effective contraceptive measures throughout the trial period (such as complete abstinence, condoms, cervical caps plus spermicides, intrauterine devices, etc.);
- Negative serum β-hCG test result during the screening period (to rule out pregnancy);
- Fully understand the trial information and sign the informed consent form.
Exclusion Criteria:
- Subjects with primary amenorrhea;
- Subjects with thyroid disorders (hypothyroidism/hyperthyroidism or thyroid malignant tumors) or resistant ovary syndrome (ROS);
- Subjects with abnormal female karyotypes (e.g., Turner syndrome, Fragile X syndrome);
- Positive serology tests (HBV antibody, HCV antibody, HIV antibody, syphilis). Exceptions: HBV carriers, patients with stable HBV after drug treatment (HBV DNA titer ≤500 IU/mL or copies <1000 copies/mL), and patients with cured HCV (negative HCV RNA test) may be enrolled if deemed eligible by the investigator;
- Subjects receiving or planning to use the following medications during the trial: oral or systemic corticosteroids, danazol, anticoagulants, Chinese herbal medicines or botanical supplements that may affect hormone levels or ovarian function;
- History of hypersensitivity to human serum albumin;
- Pregnant or breastfeeding subjects;
- Participation in another clinical trial within the past 3 months, or receipt of other cell therapies (excluding blood transfusion);
- History of malignant tumors;
- Subjects with contraindications or cautions for estrogen use, including known or suspected breast cancer, endometrial cancer, other known or suspected sex hormone-dependent malignancies, active venous or arterial thromboembolic diseases within the last 6 months, undiagnosed abnormal genital bleeding, severe hepatic or renal insufficiency [serum aspartate aminotransferase (AST) >3×ULN, serum alanine aminotransferase (ALT) >3×ULN, estimated glomerular filtration rate (eGFR) <60 mL/min], etc.;
- Uncontrolled diabetes, hypertension (>150/100 mmHg), heart disease, etc.;
- Any other conditions judged by the investigator to render the subject unsuitable for participation in this study.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Phase I, Dose Cohort 1
Human Umbilical Cord Mesenchymal Stem Cells Injection
|
hUC-MSCs Injection, administered via intravenous infusion as a single dose on D0.
其他名称:
|
|
实验性的:Phase I, Dose Cohort 2
Human Umbilical Cord Mesenchymal Stem Cells Injection
|
hUC-MSCs Injection, administered via intravenous infusion as a single dose on D0.
其他名称:
|
|
实验性的:Phase I, Dose Cohort 3
Human Umbilical Cord Mesenchymal Stem Cells Injection
|
hUC-MSCs Injection, administered via intravenous infusion as a single dose on D0.
其他名称:
|
|
实验性的:Phase IIa, Medium-Dose Cohort
Human Umbilical Cord Mesenchymal Stem Cells Injection
|
hUC-MSCs Injection, 3 infusions in total, dosing interval ≥7 days.
其他名称:
|
|
实验性的:Phase IIa, High-Dose Cohort
Human Umbilical Cord Mesenchymal Stem Cells Injection
|
hUC-MSCs Injection, 3 infusions in total, dosing interval ≥7 days.
其他名称:
|
|
安慰剂比较:Phase IIa, Placebo Cohort
Multiple Electrolytes Injection
|
3 infusions in total, dosing interval ≥7 days
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Phase I : Incidence and number of subjects with treatment-emergent adverse events and serious adverse events.
大体时间:48 weeks
|
In this Phase I stage, safety is the primary endpoint.
Types, frequencies, severities and causal relationships of all adverse events (AEs) and serious adverse events (SAEs) occurring from the first administration of study drug to the end of safety follow-up (48 weeks), assessed in accordance with the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 6.0; together with the proportion of adverse events judged by the investigator to be related to the study drug.
|
48 weeks
|
|
Phase II :FSH
大体时间:at Week 24 post-treatment
|
To evaluate the changes from baseline in serum follicle-stimulating hormone (FSH) levels at Week 24 post-treatment.
|
at Week 24 post-treatment
|
|
Phase II :E2
大体时间:at Week 24 post-treatment
|
To evaluate the changes from baseline in serum festradiol (E2) levels at Week 24 post-treatment.
|
at Week 24 post-treatment
|
|
Phase II :AMH
大体时间:at Week 24 post-treatment
|
To evaluate the changes from baseline in serum anti-Müllerian hormone (AMH) levels at Week 24 post-treatment.
|
at Week 24 post-treatment
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Phase I: FSH
大体时间:48 weeks
|
To evaluate the changes from baseline in serum follicle-stimulating hormone (FSH) levels.
|
48 weeks
|
|
Phase I :E2
大体时间:48 weeks
|
To evaluate the changes from baseline in serum estradiol (E2) levels
|
48 weeks
|
|
Phase I : AMH
大体时间:48 weeks
|
To evaluate the changes from baseline in serum anti-Müllerian hormone (AMH) levels.
|
48 weeks
|
|
Phase II: Incidence and number of subjects with treatment-emergent adverse events and serious adverse events.
大体时间:48 weeks
|
In this Phase II stage, safety is the secondary endpoint.
Types, frequencies, severities and causal relationships of all adverse events (AEs) and serious adverse events (SAEs) occurring from the first administration of study drug to the end of safety follow-up (48 weeks), assessed in accordance with the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 6.0; together with the proportion of adverse events judged by the investigator to be related to the study drug.
|
48 weeks
|
|
Phase I/II: AFC
大体时间:48 weeks
|
Changes from baseline in antral follicle count (AFC) by transvaginal ultrasound.
|
48 weeks
|
|
Phase I/II: endometrial thickness
大体时间:48 weeks
|
Changes from baseline in endometrial thickness measured by transvaginal ultrasound.
|
48 weeks
|
|
Phase I/II: menstrual recovery status
大体时间:48 weeks
|
Menstrual recovery status will be assessed via patient inquiry at each visit.
|
48 weeks
|
|
Phase I/II:Modified Kupperman Index
大体时间:48 weeks
|
To evaluate the changes in the Modified Kupperman Index from baseline across all post-baseline follow-up visits. Modified Kupperman Index will be assessed through physician interview.The total score ranges from 0 to 63 points. Total score stratification: >30 points indicates severe symptoms, 16-30 points moderate symptoms, 6-15 points mild symptoms, and <6 points normal status. |
48 weeks
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- WG108-POI-I/IIa
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.